David Kisor, R.Ph., B.S., Pharm.D.
Dr. David Kisor is a professor of pharmacokinetics and chair of the Department of Pharmaceutical and Biomedical Sciences at the Raabe College of Pharmacy at Ohio Northern University. Kisor came to ONU from GlaxoWellcome, (originally Burroughs Wellcome Co. and now GlaxoSmithKline), where he was a research scientist in Pharmacokinetics & Drug Metabolism, focusing on the development of purine analog anti-leukemia drugs, including the drug nelarabine, a derivative of guanine, one of the “building blocks of life,” that was marketed in the U.S. in 2005. His focus at ONU has been pharmacokinetics and the relationship between genetics and pharmacokinetics. He has integrated pharmacogenetics into the pharmacokinetics subject matter since 1998.
Recently, his plan for the integration of pharmacogenetics and personalized medicine throughout the six-year PharmD program at the Raabe College of Pharmacy was adopted by the college faculty at-large. In spring 2012, Kisor will offer a University-wide, public-access course on evaluation of a human genome through his blog. Additionally, he, along with Drs. Jon Sprague, Michael Kane and Jeff Talbot, is co-authoring a student-based textbook on the interface of pharmacogenetics, pharmacokinetics and pharmacodynamics in personalized medicine. Kisor also serves as the college’s representative to the Personalized Medicine Coalition. The Raabe College of Pharmacy is the only college of pharmacy in the country that belongs to the PMC, an interdisciplinary organization leading the way in the implementation of personalized medicine in the U.S.
"In history, we rarely have the opportunity to be part of something that promises to profoundly change our world. In medicine, in pharmacy, it is genomics, and our students understand this is the ‘here and now’ future of our profession. Their applications of pharmacogenomics will lead our profession to greater, positive change."
“The college has been teaching ‘personalized medicine’ for more than a decade and has committed to being a leader in pharmacogenetics education.”
“We recognize the promise of the human genome project, pharmacogenomics and personalized medicine, and are working to make personalized medicine an expectation of our students.”